ArticleMycopathologia2025
Pathogenicity Evaluation on Fluconazole-Resistant Candida auris Clade V in Murine Model.
Article in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In Vitro Activity and In Vivo Efficacy in a Murine Model of Rezafungin, Anidulafungin, Caspofungin, and Micafungin Against the Fifth Clade ofJournal of fungi (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundCandida auris, a medically multidrug-resistant fungal pathogen, has recently emerged as the primary one that poses a global public health threat. Although C. auris was first described in Japan, numerous cases of C. auris infections have been reported globally and clustered in four major clades (I, II, III, and IV). In 2019 and 2024, a potential V clade in Iran and VI clade in Bangladesh were described. Nevertheless, limited pathogenicity data of the fifth clade are available compared to the other clades. OBJECTIVES AND
methodsThis study evaluated the pathogenicity of fluconazole-resistant C. auris clade V and the therapeutic efficacy of amphotericin B in an immunocompromised mouse model, with C. albicans serving as a standard pathogen. The infection's advancement was tracked by evaluating mortality rates, fungal burden, and histopathological alterations.
resultsThe C. auris clade V strain exhibited the highest fungal load in heart and kidney tissues on days 3, 5, 7, and 10, with the lowest load observed in brain tissue. In contrast, mice infected with the C. albicans strain showed the highest fungal load in the spleen on days 3, 5, and 10 and in the heart on the 7th day post-infection. Conversely, the average survival time for mice infected with C. auris was 14 days with drug treatment, demonstrating that AMB treatment significantly improved the survival rate of mice infected with C. auris clade V.
conclusionThis study highlights the differing pathogenic behaviors of C. auris clade V and C. albicans. Although C. albicans exhibits greater virulence in untreated infections, C. auris clade V remains a serious threat, even at lower colony levels. The improved survival rates in infected mice treated with amphotericin B underscore the importance of effective therapeutic interventions. Further research is essential to enhance our understanding of these pathogens and optimize treatment protocols.
Indexed as
Identifiers
40555808What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.